Non-Hodgkin lymphoma

Non-Hodgkin lymphoma is a non-specific term that includes several lymphoproliferative malignant diseases with different clinical and histological appearances. Here, we concentrate on adult lymphomas. We look at their molecular basis, at the development of a classification system based on a better understanding of the biology of the various subgroups, and at how refinement of adverse prognostic factor groupings helps in clinical management. Lymphomas can present in various ways and be difficult to diagnose. About a quarter of cases arise extranodally and might present special problems. Developments in cytotoxic chemotherapy have led to good long-term survival prospects for aggressive lymphoma; introduction of novel approaches, including monoclonal antibody therapy, offers promise for indolent lymphoma, and should further improve prognosis for aggressive tumours.

[1]  S. Pileri,et al.  Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Levy,et al.  Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. , 1992, The New England journal of medicine.

[3]  R. Siebert,et al.  Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. Vitetta,et al.  Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. , 2001, Blood.

[5]  W. Chan,et al.  New approaches to lymphoma diagnosis. , 2001, Hematology. American Society of Hematology. Education Program.

[6]  T. C. Diss,et al.  Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori , 1993, The Lancet.

[7]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[8]  J. Ghrayeb,et al.  Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[9]  N. Schmitz,et al.  Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  W. Hiddemann,et al.  IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group , 2000, Annals of Hematology.

[11]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[12]  A. Demidem,et al.  Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. , 1997, Cancer biotherapy & radiopharmaceuticals.

[13]  J. Connors,et al.  Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. , 1987, Annals of internal medicine.

[14]  K. Maclennan,et al.  Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. , 1994, British Journal of Cancer.

[15]  B. Nathwani,et al.  Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  B. Coiffier,et al.  A multivariate analysis of the survival of patients with aggressive lymphoma: variations in the predictive value of prognostic factors during the course of the disease. Groupe d'Etudes des Lymphomes de l'Adulte. , 1998, Cancer.

[17]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[18]  A. Pileri,et al.  High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. , 1997, The New England journal of medicine.

[19]  F. Cavalli,et al.  Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. , 2002, Blood.

[20]  T. Molina,et al.  Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  L. Staudt,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[22]  B. Johansson,et al.  A breakpoint map of recurrent chromosomal rearrangements in human neoplasia , 1997, Nature Genetics.

[23]  S. Pittaluga,et al.  The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non‐intensive therapy by the British National Lymphoma Investigation Group , 1997, British journal of haematology.

[24]  M. Taniwaki,et al.  Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  R. Fisher,et al.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.

[26]  A. Santoro,et al.  Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  L. Gordon,et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.